These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Tapscott SJ; Thayer MJ; Weintraub H Science; 1993 Mar; 259(5100):1450-3. PubMed ID: 8383879 [TBL] [Abstract][Full Text] [Related]
6. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230 [TBL] [Abstract][Full Text] [Related]
7. Activation and repression of myogenesis in somatic cell hybrids: evidence for trans-negative regulation of MyoD in primary fibroblasts. Thayer MJ; Weintraub H Cell; 1990 Oct; 63(1):23-32. PubMed ID: 2208280 [TBL] [Abstract][Full Text] [Related]
8. Mutation of Thr115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells. Liu LN; Dias P; Houghton PJ Cell Growth Differ; 1998 Sep; 9(9):699-711. PubMed ID: 9751114 [TBL] [Abstract][Full Text] [Related]
9. The MyoD-inducible p204 protein overcomes the inhibition of myoblast differentiation by Id proteins. Liu CJ; Ding B; Wang H; Lengyel P Mol Cell Biol; 2002 May; 22(9):2893-905. PubMed ID: 11940648 [TBL] [Abstract][Full Text] [Related]
10. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Cocker HA; Hobbs SM; Tiffin N; Pritchard-Jones K; Pinkerton CR; Kelland LR Br J Cancer; 2001 Nov; 85(11):1746-52. PubMed ID: 11742497 [TBL] [Abstract][Full Text] [Related]
11. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Meddeb M; Valent A; Danglot G; Nguyen VC; Duverger A; Fouquet F; Terrier-Lacombe MJ; Oberlin O; Bernheim A Cytogenet Cell Genet; 1996; 73(4):325-30. PubMed ID: 8751388 [TBL] [Abstract][Full Text] [Related]
12. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632 [TBL] [Abstract][Full Text] [Related]
13. Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain. Sirri V; Leibovitch MP; Leibovitch SA Oncogene; 2003 Aug; 22(36):5658-66. PubMed ID: 12944914 [TBL] [Abstract][Full Text] [Related]
14. Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. Lassar AB; Thayer MJ; Overell RW; Weintraub H Cell; 1989 Aug; 58(4):659-67. PubMed ID: 2548731 [TBL] [Abstract][Full Text] [Related]
15. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Keleti J; Quezado MM; Abaza MM; Raffeld M; Tsokos M Am J Pathol; 1996 Jul; 149(1):143-51. PubMed ID: 8686737 [TBL] [Abstract][Full Text] [Related]
17. Regulation of muscle cell growth and differentiation by the MyoD family of helix-loop-helix proteins. Li L; Olson EN Adv Cancer Res; 1992; 58():95-119. PubMed ID: 1312291 [TBL] [Abstract][Full Text] [Related]
18. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Dilla T; Velasco JA; Medina DL; González-Palacios JF; Santisteban P Endocrinology; 2000 Jan; 141(1):420-9. PubMed ID: 10614665 [TBL] [Abstract][Full Text] [Related]
19. MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. Urashima M; Teoh G; Chauhan D; Ogata A; Shirahama S; Kaihara C; Matsuzaki M; Matsushima H; Akiyama M; Yuza Y; Maekawa K; Anderson KC Blood; 1998 Aug; 92(3):959-67. PubMed ID: 9680365 [TBL] [Abstract][Full Text] [Related]